000144846 001__ 144846 000144846 005__ 20240912134241.0 000144846 0247_ $$2doi$$a10.3390/nu16162780 000144846 0248_ $$2sideral$$a139718 000144846 037__ $$aART-2024-139718 000144846 041__ $$aeng 000144846 100__ $$aTorrijo-Belanche, Carolina 000144846 245__ $$aUrinary Phosphate and Subclinical Atherosclerosis: The AWHS Study 000144846 260__ $$c2024 000144846 5060_ $$aAccess copy available to the general public$$fUnrestricted 000144846 5203_ $$a(1) Background: Atherosclerosis is a leading cause of vascular death worldwide. High urinary phosphate has recently been identified as a cardiovascular risk factor, but its role has not been fully established. The aim of this study was to investigate the association between urinary phosphate and subclinical atherosclerosis in the carotid, femoral as well as coronary territories; (2) Methods: We performed a cross-sectional analysis of a sample of 1169 middle-aged men, aged 50.9 years (SD 3.7), without previous cardiovascular disease, belonging to the Aragon Workers Health Study (AWHS). Urinary phosphate was analyzed in urine samples using the Fiske-Subbarow method. The presence of carotid plaque and femoral plaque was assessed by ultrasound and coronary artery calcium score (CACS) by computed tomography. Demographic, anthropometric and clinical data were collected at annual medical examinations. Logistic regression models were used to estimate the prevalence of adjusted atherosclerosis in the different vascular arteries; (3) Results: A significant inverse association was observed between urinary phosphate and subclinical atherosclerosis in the carotid [OR 95% CI 0.69 (0.49–0.99)] and coronary (CACS > 200) [OR 95% CI 0.46 (0.23–0.88)] arteries; however, no statistically significant association was found between urinary phosphate and the presence of atheroma plaques in the femoral territory [OR 1.02 (0.72–1.45)]; (4) Conclusions: In middle-aged men, a higher urinary phosphate concentration is associated with a lower prevalence of subclinical carotid and coronary atherosclerosis compared with those with a lower urinary phosphate concentration. 000144846 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER-FSE/FIS/20-144$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/23-240 000144846 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000144846 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000144846 700__ $$0(orcid)0000-0003-0604-5042$$aMoreno-Franco, Belén$$uUniversidad de Zaragoza 000144846 700__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra, Martín$$uUniversidad de Zaragoza 000144846 700__ $$aGimeno-Ruiz, Sofía 000144846 700__ $$0(orcid)0000-0002-1889-3746$$aCalvo-Galiano, Naiara$$uUniversidad de Zaragoza 000144846 700__ $$aRey-García, Jimena 000144846 700__ $$aGuallar-Castillón, Pilar 000144846 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000144846 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ. 000144846 773__ $$g16, 16 (2024), 2780 [10 pp.]$$pNutrients$$tNutrients$$x2072-6643 000144846 8564_ $$s290314$$uhttps://zaguan.unizar.es/record/144846/files/texto_completo.pdf$$yVersión publicada 000144846 8564_ $$s2734997$$uhttps://zaguan.unizar.es/record/144846/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000144846 909CO $$ooai:zaguan.unizar.es:144846$$particulos$$pdriver 000144846 951__ $$a2024-09-12-13:05:42 000144846 980__ $$aARTICLE